Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: A randomized, controlled trial

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Chaiklang, Kanokporn ^a   Wipasa, Jiraprapa ^b   Chaiwarith, Romanee ^a   Praparattanapan, Jutarat ^a   Supparatpinyo, Khuanchai ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIBODY; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RECOMBINANT HEPATITIS B VACCINE; VIRUS RNA;

ADULT; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; THAILAND; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VACCINATION;

ADULT; COINFECTION; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; THAILAND; VACCINATION;

EID: 84893000793     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080409     Document Type: Article

References (26)

1. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B et al. (2005) Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19: 593-601. doi:10.1097/01.aids.0000163936.99401.fe. PubMed: 15802978. (Pubitemid 40543982)
2. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL (2003) Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 188: 571-577. doi:10.1086/377135. PubMed: 12898445. (Pubitemid 37011810)
3. Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E et al. (2005) Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 42: 799-805. doi:10.1016/j.jhep.2005.01.022. PubMed: 15973779. (Pubitemid 40693195)
4. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926. doi: 10.1016/S0140-6736(02)11913-1. PubMed: 12493258. (Pubitemid 35472132)
5. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A et al. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58: 1-207; quiz CE201-204
6. Geretti AM, Brook G, Cameron C, Chadwick D, Heyderman RS et al. (2008) British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 9: 795-848. doi:10.1111/j.1468-1293.2008.00637.x. PubMed: 18983477.
7. Loke RH, Murray-Lyon IM, Coleman JC, Evans BA, Zuckerman AJ (1990) Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. J Med Virol 31: 109-111. doi:10.1002/jmv.1890310207. PubMed: 2143776. (Pubitemid 20213237)
8. da Mota Silveira Sasaki MG, Sobroza De Mello R, Focaccia Siciliano R, Wang Lda Mota Silveira Sasaki MG, Sobroza De Mello R, Focaccia Siciliano R, Wang L (1998) Response of HIV/AIDS Patients to Hepatitis B Recombinant Vaccine. Braz J Infect Dis 2: 236-240. PubMed: 11103014.
9. Kalinowska-Nowak A, Bociaga-Jasik M, Garlicki A, Mach T (2007) [Efficacy of vaccination against hepatitis B in adult with HIV infection]. Przegl Epidemiol 61: 339-347. PubMed: 17956052.
10. Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L et al. (2011) Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 305: 1432-1440. doi:10.1001/jama. 2011.351. PubMed: 21486976.
11. André FE (1989) Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 87: 14S-20S. doi: 10.1016/0002-9343(89)90525-1. PubMed: 2528292.
12. Zajac BA, West DJ, McAleer WJ, Scolnick EM (1986) Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 13 Suppl A: 39-45. doi:10.1016/S0163-4453(86)92668-X. PubMed: 2943814.
13. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Kauffmann RH, Leyten EM et al. (2011) A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis 203: 984-991. doi:10.1093/infdis/jiq137. PubMed: 21266513.
14. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M et al. (2009) Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 27: 17-22. doi:10.1016/j.vaccine.2008.10.040. PubMed: 18984022.
15. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M (2005) Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double-dose. Vaccine 23: 2902-2908. doi:10.1016/j.vaccine.2004.11.057. PubMed: 15780739. (Pubitemid 40386492)
16. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A et al. (2005) Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 19: 221-240. doi:10.1097/01.aids.0000192093. 46506.e5. PubMed: 15718833. (Pubitemid 40396554)
17. Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P et al. (2000) Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 18: 1161-1165. doi:10.1016/S0264-410X(99)00389-8. PubMed: 10649616.
18. the Royal College of Physicians of; Thailand. Recommended Adult and Elderly Immunization Schedule (In Thai) (2012). Available: http://www.rcpt.org/ index.php/2012-10-03-16-53-39/category/6-2013-02-02-09-02-52.html?download= 56%3A2013-02-02-09-08-53. Accessed 30 January 2013.
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649. doi:10.1002/bjs.1800600817. PubMed: 4541913.
20. Paitoonpong L, Suankratay C (2008) Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis 40: 54-58. doi: 10.1080/ 00365540701522975. PubMed: 17852939.
21. Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC et al. (2012) Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 30: 5973-5977. doi:10.1016/j.vaccine.2012.07.028. PubMed: 22828589.
22. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN et al. (1986) Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 315: 209-214. doi:10.1056/NEJM198607243150401. PubMed: 2941687. (Pubitemid 16097121)
23. Gesemann M, Scheiermann N (1995) Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 13: 443-447. doi:10.1016/0264-410X(94)00010-K. PubMed: 7639012.
24. Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M et al. (2005) Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366: 1379-1384. doi: 10.1016/S0140-6736(05)67568-X. PubMed: 16226616. (Pubitemid 41443405)
25. Van Damme P, Van Herck K (2007) A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 5: 79-84. doi:10.1016/j.tmaid.2006.04.004. PubMed: 17298912. (Pubitemid 46211211)
26. Gabbuti A, Romanò L, Blanc P, Meacci F, Amendola A et al. (2007) Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 25: 3129-3132. doi:10.1016/j.vaccine.2007.01.045. PubMed: 17291637. (Pubitemid 46482746)